Physician profile
Robert Maresh
NPI 1821159484
$1,048.87
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $231 · 2020: $21.47 · 2021: $104 · 2022: $369 · 2023: $206 · 2024: $117.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $323.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $323.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $404.65 | 2019-2023 | Vivitrol |
| Indivior INC. | $188.32 | 2019-2023 | Perseris |
| Abbvie INC. | $117.30 | 2024 | |
| Lundbeck LLC | $87.20 | 2022-2023 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $54.66 | 2022-2023 | Austedo |
| Corium, LLC | $44.63 | 2022-2023 | Azstarys |
| Gilead Sciences, INC. | $44.38 | 2019 | |
| Janssen Pharmaceuticals, INC | $33.75 | 2023 | Spravato, Invega Sustenna |
| Otsuka America Pharmaceutical, INC. | $28.79 | 2022-2023 | Rexulti, Abilify Maintena |
| Kaleo, INC. | $18.48 | 2019 | |
| Neurocrine Biosciences, INC. | $13.84 | 2022 | |
| Vanda Pharmaceuticals INC. | $12.87 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Maresh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.